Article PDF
Avoid common mistakes on your manuscript.
References
Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis, part I: Diagnostic pathway. J Am Acad Dermatol. 2011;65:1–14.
Smack D, Norton SA, Fitzpatrick JE. Proposal for a pathogenesis-based classification of tumoral calcinosis. Int J Dermatol. 1996;35:265–71.
Hershkovitz D, Gross Y, Nahum S, et al. Functional characterization of SAMD9, a protein deficient in normophosphatemic familial tumoral calcinosis. J Invest Dermatol. 2011;131:662–69.
Ichikawa S, Baujat G, Seyahi A, et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A. 2010; 152A:896–903.
Balachandran K, Kamalanathan S, Sahoo JP, Das AK, Halanaik D. Differential response of idiopathic sporadic tumoral calcinosis to bisphosphonates. Indian J Endocr Metab. 2014;18:521–25.
Jacob JJ, Mathew K, Thomas N. Idiopathic sporadic tumoral calcinosis of the hip: successful oral bisphosphonate therapy. Endocr Pract. 2007;13:182–86.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Soumya, S., Prasad, N., Jabbar, P.K. et al. Beneficial Response to Phosphate Lowering Therapy in Normophosphatemic Tumoral Calcinosis. Indian Pediatr 58, 88–89 (2021). https://doi.org/10.1007/s13312-021-2109-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-021-2109-6